Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Classement en actions #16882
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Prix de l'action
$2.52
Capitalisation boursière
$274.65M
Changement (1 jour)
0.46%
Changement (1 an)
-56.11%
Pays
CN
Échange VISEN Pharmaceuticals (2561)

Catégorie

Ratio P/S pour VISEN Pharmaceuticals (2561)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de VISEN Pharmaceuticals, le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour VISEN Pharmaceuticals de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes